PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Instead, in obese youths carrying the PNPLA3 rs738409 genotype with NAFLD, the intention of the precise therapy is to increase the intake of n-3 PUFA and to decrease n-6 PUFA, glucose, sucrose, and fructose derivates from soft drinks, with physical activation and, according to N. Santoro, with “the dear and old diet, always a fundamental and irreplaceable NAFLD therapy” [94].